Financial Lp Hrt Sells 53,867 Shares of Onconetix (NASDAQ:ONCO) Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt sold 53,867 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $0.73, for a total value of $39,322.91. Following the sale, the insider owned 143,185 shares in the company, valued at approximately $104,525.05. This trade represents a 27.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, April 21st, Financial Lp Hrt sold 49,710 shares of Onconetix stock. The stock was sold at an average price of $0.69, for a total value of $34,299.90.
• On Monday, April 20th, Financial Lp Hrt sold 94,462 shares of Onconetix stock. The stock was sold at an average price of $0.75, for a total value of $70,846.50.
• On Friday, April 17th, Financial Lp Hrt purchased 34,636 shares of Onconetix stock. The shares were bought at an average price of $0.73 per share, for a total transaction of $25,284.28.
• On Wednesday, April 15th, Financial Lp Hrt purchased 92,554 shares of Onconetix stock. The shares were bought at an average price of $0.76 per share, for a total transaction of $70,341.04.
• On Tuesday, April 14th, Financial Lp Hrt purchased 74,350 shares of Onconetix stock. The shares were bought at an average price of $0.77 per share, for a total transaction of $57,249.50.

Onconetix Price Performance

Shares of NASDAQ ONCO opened at $0.73 on Thursday. The stock’s 50-day moving average is $2.45 and its two-hundred day moving average is $8.45. Onconetix, Inc. has a 1-year low of $0.66 and a 1-year high of $74.29. The company has a market cap of $477,371.20, a price-to-earnings ratio of 0.00 and a beta of 3.63.

Institutional Investors Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned 0.84% of Onconetix at the end of the most recent reporting period. Institutional investors and hedge funds own 23.89% of the company’s stock.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.